Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
Clinical trial NCT05469009 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05469009
- Sponsor
- Ali Rezai
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-14
- Primary completion
- 2029-07-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.